These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12852440)

  • 21. Acute decrease of cardio-ankle vascular index with the administration of beraprost sodium.
    Takahashi M; Shiba T; Hirano K; Hitsumoto T; Shirai K
    J Atheroscler Thromb; 2012; 19(5):479-84. PubMed ID: 22659532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans.
    Matsumoto T; Iwasa K; Kyuragi R; Honma K; Guntani A; Ohmine T; Itoh H; Onohara T; Maehara Y
    Int Angiol; 2010 Apr; 29(2 Suppl):49-54. PubMed ID: 20357749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes.
    Wang LN; Tang Z; Shou I; Fukui M; Tomino Y
    Nephron; 1996; 73(4):637-43. PubMed ID: 8856263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.
    Akagi S; Nakamura K; Matsubara H; Kondo M; Miura D; Matoba T; Egashira K; Ito H
    J Cardiovasc Pharmacol; 2016 Apr; 67(4):290-8. PubMed ID: 26745002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
    Maeda H; Nakamura H; Fang J
    Adv Drug Deliv Rev; 2013 Jan; 65(1):71-9. PubMed ID: 23088862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.
    Lièvre M; Morand S; Besse B; Fiessinger JN; Boissel JP
    Circulation; 2000 Jul; 102(4):426-31. PubMed ID: 10908215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a stable prostacyclin analogue beraprost sodium on VEGF and PAI-1 gene expression in vascular smooth muscle cells.
    Atsuta H; Uchiyama T; Kanai H; Iso T; Tanaka T; Suga T; Maeno T; Arai M; Nagai R; Kurabayashi M
    Int J Cardiol; 2009 Mar; 132(3):411-8. PubMed ID: 18471910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice.
    Inoue E; Ichiki T; Takeda K; Matsuura H; Hashimoto T; Ikeda J; Kamiharaguchi A; Sunagawa K
    J Endocrinol; 2012 Jun; 213(3):285-91. PubMed ID: 22460613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of beraprost sodium (Procylin), a stable prostaglandin I2 analogue, on a dorsal skin flap model in rats.
    Alexandrou K; Hata Y; Matsuka K; Matsuda H
    Scand J Plast Reconstr Surg Hand Surg; 1996 Mar; 30(1):17-22. PubMed ID: 8711437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood-brain-barrier transport of lipid microspheres containing clinprost, a prostaglandin I2 analogue.
    Minagawa T; Sakanaka K; Inaba S; Sai Y; Tamai I; Suwa T; Tsuji A
    J Pharm Pharmacol; 1996 Oct; 48(10):1016-22. PubMed ID: 8953502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin-induced diabetic rats.
    Ueno Y; Koike H; Nakamura Y; Ochi Y; Annoh S; Nishio S
    Jpn J Pharmacol; 1996 Feb; 70(2):177-82. PubMed ID: 8866755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways.
    Niwano K; Arai M; Tomaru K; Uchiyama T; Ohyama Y; Kurabayashi M
    Circ Res; 2003 Sep; 93(6):523-30. PubMed ID: 12919953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease.
    Ohata S; Ishibashi Y; Shimada T; Takahashi N; Sugamori T; Sakane T; Hirano Y; Oyake N; Murakami Y; Higami T
    Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):381-7. PubMed ID: 16620305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus.
    Goya K; Otsuki M; Xu X; Kasayama S
    Metabolism; 2003 Feb; 52(2):192-8. PubMed ID: 12601631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of long-term administration of a prostacyclin analogue (beraprost sodium) on myocardial fibrosis in Dahl rats.
    Kaneshige T; Saida Y; Tanaka R; Soda A; Fukushima A; Ida N; Takenaka M; Yamane Y
    J Vet Med Sci; 2007 Dec; 69(12):1271-6. PubMed ID: 18176024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostaglandin I
    Kumei S; Yuhki KI; Kojima F; Kashiwagi H; Imamichi Y; Okumura T; Narumiya S; Ushikubi F
    FASEB J; 2018 May; 32(5):2354-2365. PubMed ID: 29247122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels.
    Ningaraj NS; Rao M; Hashizume K; Asotra K; Black KL
    J Pharmacol Exp Ther; 2002 Jun; 301(3):838-51. PubMed ID: 12023511
    [